IL108114A - Drug combination of amplified glutathione interferon - Google Patents

Drug combination of amplified glutathione interferon

Info

Publication number: IL108114A
Authority: IL; Israel
Prior art keywords: interferon; hepatitis; human; human interferon; treatment
Prior art date: 1992-12-22

Application number

IL10811493A

Other languages

English (en)

Hebrew (he)

Other versions

IL108114A0 (en

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-22

Filing date

1993-12-21

Publication date

1999-12-31

1993-12-21 Application filed by Wellcome Found filed Critical Wellcome Found

1994-04-12 Publication of IL108114A0 publication Critical patent/IL108114A0/xx

1999-12-31 Publication of IL108114A publication Critical patent/IL108114A/en

Links

RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims description 61
229960003180 glutathione Drugs 0.000 title claims description 34
108010024636 Glutathione Proteins 0.000 title claims description 17
102000014150 Interferons Human genes 0.000 title abstract description 88
108010050904 Interferons Proteins 0.000 title abstract description 88
229940079322 interferon Drugs 0.000 title abstract description 75
230000001225 therapeutic effect Effects 0.000 title abstract description 5
238000011282 treatment Methods 0.000 claims abstract description 52
239000002243 precursor Substances 0.000 claims abstract description 33
239000000411 inducer Substances 0.000 claims abstract description 30
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 35
229960004308 acetylcysteine Drugs 0.000 claims description 35
208000005176 Hepatitis C Diseases 0.000 claims description 23
208000006454 hepatitis Diseases 0.000 claims description 18
208000002672 hepatitis B Diseases 0.000 claims description 18
108010047761 Interferon-alpha Proteins 0.000 claims description 12
102000006992 Interferon-alpha Human genes 0.000 claims description 12
208000010710 hepatitis C virus infection Diseases 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 10
238000000034 method Methods 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
206010008909 Chronic Hepatitis Diseases 0.000 claims description 7
235000018417 cysteine Nutrition 0.000 claims description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 abstract description 27
239000002516 radical scavenger Substances 0.000 abstract description 24
229940123457 Free radical scavenger Drugs 0.000 abstract description 22
238000002648 combination therapy Methods 0.000 abstract description 4
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 19
108010082126 Alanine transaminase Proteins 0.000 description 19
241000700605 Viruses Species 0.000 description 18
210000004027 cell Anatomy 0.000 description 16
229940047124 interferons Drugs 0.000 description 16
150000003254 radicals Chemical class 0.000 description 15
210000002966 serum Anatomy 0.000 description 14
231100000283 hepatitis Toxicity 0.000 description 13
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
210000002381 plasma Anatomy 0.000 description 10
208000006154 Chronic hepatitis C Diseases 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
230000001684 chronic effect Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000009385 viral infection Effects 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
208000036142 Viral infection Diseases 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
241000711549 Hepacivirus C Species 0.000 description 5
206010019799 Hepatitis viral Diseases 0.000 description 5
239000000047 product Substances 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
201000001862 viral hepatitis Diseases 0.000 description 5
206010016654 Fibrosis Diseases 0.000 description 4
230000007882 cirrhosis Effects 0.000 description 4
208000019425 cirrhosis of liver Diseases 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000036542 oxidative stress Effects 0.000 description 4
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 3
208000005331 Hepatitis D Diseases 0.000 description 3
102000003996 Interferon-beta Human genes 0.000 description 3
108090000467 Interferon-beta Proteins 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
208000005252 hepatitis A Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
108010006088 interferon alfa-n1 Proteins 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000000510 mucolytic effect Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000001603 reducing effect Effects 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
206010059313 Anogenital warts Diseases 0.000 description 2
208000000419 Chronic Hepatitis B Diseases 0.000 description 2
206010019755 Hepatitis chronic active Diseases 0.000 description 2
101001054334 Homo sapiens Interferon beta Proteins 0.000 description 2
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108700012920 TNF Proteins 0.000 description 2
108090000340 Transaminases Proteins 0.000 description 2
230000004913 activation Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
102000043557 human IFNG Human genes 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
229960001388 interferon-beta Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000002000 scavenging effect Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
102000014898 transaminase activity proteins Human genes 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LAXXPOJCFVMVAX-ZETCQYMHSA-N (2s)-2-amino-4-butylsulfanylbutanoic acid Chemical compound CCCCSCC[C@H](N)C(O)=O LAXXPOJCFVMVAX-ZETCQYMHSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
206010065051 Acute hepatitis C Diseases 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
108091028075 Circular RNA Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000000907 Condylomata Acuminata Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
101710112752 Cytotoxin Proteins 0.000 description 1
IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000724675 Hepatitis E virus Species 0.000 description 1
206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
208000037262 Hepatitis delta Diseases 0.000 description 1
241000724709 Hepatitis delta virus Species 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
206010023849 Laryngeal papilloma Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000001621 Mucoproteins Human genes 0.000 description 1
108010093825 Mucoproteins Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000726445 Viroids Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
201000004201 anogenital venereal wart Diseases 0.000 description 1
239000000729 antidote Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
201000010284 hepatitis E Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
201000000089 larynx squamous papilloma Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005976 liver dysfunction Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
208000012237 paracetamol poisoning Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000003019 stabilising effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3476—Powered trocars, e.g. electrosurgical cutting, lasers, powered knives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3494—Trocars; Puncturing needles with safety means for protection against accidental cutting or pricking, e.g. limiting insertion depth, pressure sensors
- A61B17/3496—Protecting sleeves or inner probes; Retractable tips
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1487—Trocar-like, i.e. devices producing an enlarged transcutaneous opening
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/32075—Pullback cutting; combined forward and pullback cutting, e.g. with cutters at both sides of the plaque
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3209—Incision instruments
- A61B17/3211—Surgical scalpels, knives; Accessories therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3474—Insufflating needles, e.g. Veress needles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00184—Moving parts
- A61B2018/0019—Moving parts vibrating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
- A61M13/003—Blowing gases other than for carrying powders, e.g. for inflating, dilating or rinsing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Surgery (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Medical Informatics (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Otolaryngology (AREA)
Plasma & Fusion (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL10811493A 1992-12-22 1993-12-21 Drug combination of amplified glutathione interferon IL108114A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB929226729A GB9226729D0 (en)	1992-12-22	1992-12-22	Therapeutic combination

Publications (2)

Publication Number	Publication Date
IL108114A0 IL108114A0 (en)	1994-04-12
IL108114A true IL108114A (en)	1999-12-31

Family

ID=10727038

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10811493A IL108114A (en)	1992-12-22	1993-12-21	Drug combination of amplified glutathione interferon

Country Status (24)

Country	Link
US (1)	US5830455A (no)
EP (1)	EP0675730B1 (no)
JP (2)	JP2849214B2 (no)
KR (1)	KR100309059B1 (no)
CN (1)	CN1094642A (no)
AT (1)	ATE199643T1 (no)
AU (1)	AU680858B2 (no)
CA (1)	CA2152389A1 (no)
DE (1)	DE69330032T2 (no)
ES (1)	ES2156150T3 (no)
FR (1)	FR2699407A1 (no)
GB (1)	GB9226729D0 (no)
HR (1)	HRP931510A2 (no)
HU (1)	HUT72965A (no)
IL (1)	IL108114A (no)
IT (1)	IT1261949B (no)
MY (1)	MY141415A (no)
NO (1)	NO952469L (no)
PL (1)	PL309398A1 (no)
RU (1)	RU2145235C1 (no)
TW (1)	TW286283B (no)
WO (1)	WO1994014473A1 (no)
YU (1)	YU79393A (no)
ZA (1)	ZA939583B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
DE4325547C2 (de) *	1993-07-29	1997-11-27	Max Planck Gesellschaft	Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
US6020205A (en) *	1998-04-10	2000-02-01	Immunosciences Lab, Inc.	Determination of intracellular antioxidant levels
RU2156134C2 (ru) *	1998-05-12	2000-09-20	ООО "Формавит"	Биофармацевтический препарат на основе живой культуры bacillus и способ лечения заболевания инфекционной природы
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) *	2000-05-26	2013-07-10	イデニクス（ケイマン）リミテツド	フラビウイルスおよびペスチウイルス治療のための方法および組成物
US6878364B2 (en) *	2000-12-01	2005-04-12	Cornell Research Foundation, Inc.	Animal model for flaviviridae infection
US6759061B2 (en) *	2001-08-31	2004-07-06	Renew Life, Inc.	Liver function improvement formulation
JP2005504087A (ja) *	2001-09-28	2005-02-10	イデニクス（ケイマン）リミテツド	４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
EP1450810A4 (en) *	2001-11-16	2005-11-30	Uab Research Foundation	XANTHINE INHIBITION
CN103275159A (zh)	2002-06-28	2013-09-04	埃迪尼克斯医药公司	用于治疗黄病毒感染的修饰的2’和3’-核苷前药
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en)	2002-06-28	2007-10-26	Idenix Cayman Ltd	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004002422A2 (en)	2002-06-28	2004-01-08	Idenix (Cayman) Limited	2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2004155777A (ja) *	2002-10-16	2004-06-03	Asahi Kasei Pharma Kk	Ｃ型慢性肝炎治療剤
SI1576138T1 (sl)	2002-11-15	2017-07-31	Idenix Pharmaceuticals Llc	2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
JP2006514094A (ja) *	2002-11-29	2006-04-27	ゲーペーツェーバイオテックアクチェンゲゼルシャフト	Ｃ型肝炎ウイルス感染に対して有用な製剤
AU2003300901A1 (en)	2002-12-12	2004-06-30	Idenix (Cayman) Limited	Process for the production of 2'-branched nucleosides
RU2005133093A (ru) *	2003-03-28	2006-07-27	Фармассет, Инк. (Us)	Соединения для лечения флавивирусных инфекций
EP2345657A1 (en)	2003-05-30	2011-07-20	Pharmasset, Inc.	Modified fluorinated nucleoside analogues
WO2005007640A1 (ja)	2003-07-22	2005-01-27	Kyowa Hakko Kogyo Co., Ltd.	ウィルス感染症の予防または治療用組成物
EP1658302B1 (en) *	2003-07-25	2010-08-25	IDENIX Pharmaceuticals, Inc.	Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2005018330A1 (en) *	2003-08-18	2005-03-03	Pharmasset, Inc.	Dosing regimen for flaviviridae therapy
JP2005104852A (ja) *	2003-09-29	2005-04-21	Kyowa Hakko Kogyo Co Ltd	モービリウィルス感染症の予防または治療用組成物
KR20070011451A (ko)	2004-05-05	2007-01-24	예일 유니버시티	신규의 항바이러스 헬리오크산틴 유사체
CN101023094B (zh)	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PL3109244T3 (pl)	2004-09-14	2019-09-30	Gilead Pharmasset Llc	Wytwarzanie 2'fluoro-2'-alkilo-podstawionych lub innych ewentualnie podstawionych rybofuranozylopirymidyn i puryn oraz ich pochodnych
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
CU23432B6 (es)	2005-11-02	2009-10-16	Ct Ingenieria Genetica Biotech	Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
CA2634749C (en)	2005-12-23	2014-08-19	Idenix Pharmaceuticals, Inc.	Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
TW200946541A (en) *	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
CN102753563A (zh)	2008-12-23	2012-10-24	吉利德制药有限责任公司	核苷类似物
PA8855601A1 (es)	2008-12-23	2010-07-27		Forformidatos de nucleósidos
WO2010075554A1 (en)	2008-12-23	2010-07-01	Pharmasset, Inc.	Synthesis of purine nucleosides
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
JP6058528B2 (ja)	2010-03-31	2017-01-11	ギリアドファーマセットエルエルシー	ヌクレオシドホスホルアミデート
US10838095B2 (en)	2010-08-05	2020-11-17	Pgs Geophysical As	Wavefield deghosting of seismic data recorded using multiple seismic sources at different water depths
JP6069215B2 (ja)	2010-11-30	2017-02-01	ギリアドファーマセットエルエルシー	化合物
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
US8809354B2 (en)	2011-12-31	2014-08-19	Sheikh Riazuddin	3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
PL3038601T3 (pl)	2013-08-27	2020-08-24	Gilead Pharmasset Llc	Formulacja złożona dwóch związków przeciwwirusowych

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1526205A (en) *	1974-11-07	1978-09-27	Searle & Co	Treatment of interferon-like material
US4100150A (en) *	1975-11-04	1978-07-11	G. D. Searle & Co.	Stabilization of interferon against mechanical stress using thioctic acid
US4762705A (en) *	1981-11-10	1988-08-09	Adolf W. Schwimmer	Cancer therapy with interferon
US4927762A (en) *	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
CH666814A5 (it) *	1986-07-24	1988-08-31	Inpharzam Int Sa	Composizione farmaceutica idrosolubile contenente n-acetil-cisteina.
CA1321349C (en) *	1986-11-21	1993-08-17	Robert Zimmerman	Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein
US4985241A (en) *	1986-11-21	1991-01-15	Cetus Corporation	Therapeutic combination of free-radical scavenger and tumor necrosis factor
IT1231012B (it) *	1989-07-27	1991-11-08	Zambon Spa	Composizione farmaceutica per uso orale contenente nac.
US5248697A (en) *	1990-09-20	1993-09-28	Brigham And Women's Hospital	Enhancement of glutathione levels with glutamine
ES2082908T3 (es) *	1990-11-19	1996-04-01	Manz Galvano Technik Gmbh	Dispositivo de drenaje y llaves de paso para tambores de inmersion en el tratamiento por galvanizado y/o quimico de superficies exteriores de piezas en masa.

1992
- 1992-12-22 GB GB929226729A patent/GB9226729D0/en active Pending
1993
- 1993-04-12 TW TW082102718A patent/TW286283B/zh active
- 1993-12-20 AU AU57076/94A patent/AU680858B2/en not_active Ceased
- 1993-12-20 HU HU9501841A patent/HUT72965A/hu unknown
- 1993-12-20 WO PCT/GB1993/002600 patent/WO1994014473A1/en active IP Right Grant
- 1993-12-20 ES ES94902910T patent/ES2156150T3/es not_active Expired - Lifetime
- 1993-12-20 DE DE69330032T patent/DE69330032T2/de not_active Expired - Fee Related
- 1993-12-20 AT AT94902910T patent/ATE199643T1/de not_active IP Right Cessation
- 1993-12-20 CA CA002152389A patent/CA2152389A1/en not_active Abandoned
- 1993-12-20 KR KR1019950702659A patent/KR100309059B1/ko not_active IP Right Cessation
- 1993-12-20 EP EP94902910A patent/EP0675730B1/en not_active Expired - Lifetime
- 1993-12-20 RU RU95113492A patent/RU2145235C1/ru active
- 1993-12-20 JP JP6514930A patent/JP2849214B2/ja not_active Expired - Lifetime
- 1993-12-20 YU YU79393A patent/YU79393A/sh unknown
- 1993-12-20 PL PL93309398A patent/PL309398A1/xx unknown
- 1993-12-21 HR HR931510A patent/HRP931510A2/hr not_active Application Discontinuation
- 1993-12-21 JP JP5322685A patent/JPH06234657A/ja active Pending
- 1993-12-21 FR FR9315349A patent/FR2699407A1/fr active Pending
- 1993-12-21 MY MYPI93002794A patent/MY141415A/en unknown
- 1993-12-21 IT ITRM930840A patent/IT1261949B/it active IP Right Grant
- 1993-12-21 ZA ZA939583A patent/ZA939583B/xx unknown
- 1993-12-21 CN CN93121281A patent/CN1094642A/zh active Pending
- 1993-12-21 IL IL10811493A patent/IL108114A/en active IP Right Grant
1995
- 1995-06-20 NO NO952469A patent/NO952469L/no not_active Application Discontinuation
1996
- 1996-09-06 US US08/706,645 patent/US5830455A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IT1261949B (it)	1996-06-04
YU79393A (sh)	1996-10-09
EP0675730A1 (en)	1995-10-11
NO952469D0 (no)	1995-06-20
CN1094642A (zh)	1994-11-09
DE69330032T2 (de)	2001-09-06
ZA939583B (en)	1995-05-22
JP2849214B2 (ja)	1999-01-20
PL309398A1 (en)	1995-10-02
EP0675730B1 (en)	2001-03-14
RU2145235C1 (ru)	2000-02-10
WO1994014473A1 (en)	1994-07-07
AU5707694A (en)	1994-07-19
US5830455A (en)	1998-11-03
MY141415A (en)	2010-04-30
TW286283B (no)	1996-09-21
ITRM930840A0 (it)	1993-12-21
GB9226729D0 (en)	1993-02-17
NO952469L (no)	1995-06-20
HU9501841D0 (en)	1995-08-28
JPH08504799A (ja)	1996-05-21
KR100309059B1 (ko)	2002-06-20
FR2699407A1 (fr)	1994-06-24
AU680858B2 (en)	1997-08-14
CA2152389A1 (en)	1994-07-07
ITRM930840A1 (it)	1995-06-21
HRP931510A2 (en)	1995-12-31
ATE199643T1 (de)	2001-03-15
ES2156150T3 (es)	2001-06-16
JPH06234657A (ja)	1994-08-23
DE69330032D1 (de)	2001-04-19
HUT72965A (en)	1996-06-28
IL108114A0 (en)	1994-04-12

Legal Events

Date	Code	Title	Description
2000-06-29	FF	Patent granted

Publication	Publication Date	Title
AU680858B2 (en)	1997-08-14	Therapeutic combination containing interferon
Beloqui et al.	1993	N-acetyl cysteine enhances the response to interferon-α in chronic hepatitis C: a pilot study
RU2128056C1 (ru)	1999-03-27	Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами
Bonkovsky	1997	Therapy of hepatitis C: other options
CZ231998A3 (cs)	1999-03-17	Použití konvenčního interferonu
US7678774B2 (en)	2010-03-16	Treating severe acute respiratory syndrome
Podzamczer et al.	1993	Low‐dose interferon alpha combined with zidovudine in patients with AIDS‐associated Kaposi's sarcoma
AU681350B2 (en)	1997-08-28	Inhibitiion of retrovirus infection
AU746648B2 (en)	2002-05-02	Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
SI9300671A (sl)	1995-08-31	Terapevtska kombinacija, ki vsebuje humani interferon, uporabna za zdravljenje virusnih in nevirusnih infekcij
AU2006339220A1 (en)	2007-09-07	Pharmaceutical composition for treatment of blood clotting disorder
KR20140007927A (ko)	2014-01-20	C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
KR20050101184A (ko)	2005-10-20	에이치씨이브이 조합 요법
Sarin	2000	What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C?
WO2018134260A1 (en)	2018-07-26	Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
MXPA00002570A (en)	2001-03-05	Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c